TNON

0.89728.97%
RK

Robert K. Weigle

Independent Director

Mr. Robert K. Weigle, also known as Rob, serves as Director and Advisor since May 2026 and served as the Chief Executive Officer of NOWDiagnostics, Inc., since April 1, 2023 until May 2026. Mr. Robert has been with Prime Genomics since October 2020 and serves as its Chief Executive Officer. He serves as an Independent Director at Tenon Medical, Inc. since April 2022. Mr. Weigle was the Chief Executive Officer of Benvenue Medical, Inc., from May 2009 until August 2020. At Benvenue Mr. Weigle led growth from pre-clinical to successful clinical trials to commercial launch of first generation devices in two distinct markets, one for the treatment of compression fractures in the spine and the second for the treatment of degenerative disc disease. He oversaw all early aspects of corporate strategy, including defining, communicating and executing Benvenue’s overall business model; and represented Benvenue to the investment community. He was also a senior executive at numerous healthcare/medical device companies, including TherOx, Inc, Cardiac Pathways, Baxter Healthcare and Cardima Corporation. He also has relevant experience at Johnson & Johnson. He was Vice President of Sales, Marketing & Reimbursement at TherOx, Inc. since February 2002. He has experience in medical devices, including relevant neuro/spine experience at Johnson & Johnson, Baxter, Aesculap and Neurocare. He served as Vice President of Worldwide Sales and Marketing at Cardiac Pathways Corp. from February 2000 to January 2002. He was a Director of Benvenue Medical, Inc., from May 2009 until August 2020. Mr. Weigle received a B.A. degree in Political Science from the University of California, Berkeley.

Positions